Patents by Inventor Claude Wildmann

Claude Wildmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HLA-CW 1601/MAGE-1 DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS
    Patent number: 6680056
    Abstract: Peptides which satisfy the formula of SEQ ID NO: 10 bind to HLA-Cw*1601 molecules, and stimulate proliferation of cytolytic T cells. Examples of such peptides are those set forth in SEQ ID NOS: 4 and 5.
    Type: Grant
    Filed: August 8, 2000
    Date of Patent: January 20, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Jean-Pierre Szikora, Pierre Coulie, Claude Wildmann, Pascale Boël, Thierry Boon-Falleur
  • Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens
    Patent number: 6638512
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: October 28, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Bo{haeck over (e)}l, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • Method for determining BAGE expression
    Publication number: 20030138854
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Application
    Filed: February 20, 2002
    Publication date: July 24, 2003
    Inventors: Pascale Boel, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereof
    Patent number: 6465184
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: October 15, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Bo{haeck over (e)}l, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • Methods for determining complexes of tumor rejection antigens and HLA-Cw*160/molecules
    Patent number: 6110694
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: August 29, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Boel, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereof
    Patent number: 5877017
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: March 2, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Boel, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld